AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
AEON Biopharma, Inc. (AEON), a Delaware corporation, filed this Current Report on Form 8-K on April 3, 2026, regarding events occurring on March 31, 2026. The Company is an emerging growth company with its Class A Common Stock listed on NYSE American.
Key Financial Metrics
- Stockholders' Equity: The Company reported a stockholders' deficit of approximately $55 million as of December 31, 2025.
- Profitability: The Company has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years.
- Liquidity and Debt: The filing text does not provide specific values for cash flow, total debt, or current liquidity ratios.
Material Changes and Listing Status
On March 31, 2026, AEON received an additional written notice of non-compliance from NYSE American. The Company failed to meet Section 1003(a)(ii) of the NYSE American Company Guide, which requires stockholders' equity of at least $4.0 million for companies reporting losses in three of their four most recent fiscal years. This follows a prior notice regarding Section 1003(a)(i) (requiring $2.0 million equity) issued in February 2025.
The Company's stock continues to trade on NYSE American with a ".BC" indicator denoting non-compliance. The receipt of this notice does not immediately affect the listing status or business operations.
Outlook, Management Commentary, and Risks
AEON previously submitted a plan to regain compliance, which was accepted by NYSE American in April 2025. The Company has until August 3, 2026 (the "Plan Period") to satisfy the listing standards. Management intends to continue executing this plan but noted there is no assurance that compliance will be achieved within the required timeframe.
The Company retains the right to appeal a staff delisting determination. Forward-looking statements regarding the plan to regain compliance are subject to risks and uncertainties detailed in the Company's Form 10-K for the year ended December 31, 2025.
Investor Verification Checklist
- Verify the specific details of the compliance plan accepted by NYSE American in April 2025.
- Review the Form 10-K filed on March 30, 2026, for the full breakdown of the $55 million stockholders' deficit and recent loss history.
- Monitor the ".BC" trading indicator and the Company's inclusion on the NYSE American list of noncompliant issuers.
- Assess the timeline for the August 3, 2026, deadline to regain compliance and the potential for delisting if the plan fails.